Sign in

RAPH on OTC

Raphael Pharmaceutical Inc.

Raphael Pharmaceutical Inc. is an American medicinal chemicals and botanical products company.1 It is headquartered in Las Vegas, Nevada.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with another stock.

  • TickerRAPH on OTC1
  • IndustryMedicinal Chemicals & Botanical Products1
  • HeadquartersLas Vegas, Nevada1
  • Incorporated inNV2
  • Business addressSuite 105 - 5348 Vegas Dr., Las Vegas, Nv 891082
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

“RaphaWell” formula has undergone clinical testing, which to our belief, proved its credibility and efficacy.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income45678-$1.2M in 2025+76% since 2020
-$4.0M-$3.0M-$2.0M-$1.0M02020: -$706.0K-$706.0K20202021: -$1.6M-$1.6M2021+131%2022: -$3.3M-$3.3M2022+104%2023: -$1.3M-$1.3M2023−60%2024: -$1.5M-$1.5M2024+13%2025: -$1.2M-$1.2M2025−17%
Net income45678-$1.3M in 2025+78% since 2020
-$4.0M-$3.0M-$2.0M-$1.0M02020: -$718.0K-$718.0K20202021: -$1.6M-$1.6M2021+126%2022: -$3.4M-$3.4M2022+107%2023: -$1.3M-$1.3M2023−60%2024: -$1.5M-$1.5M2024+13%2025: -$1.3M-$1.3M2025−16%

Every line of the income statement as filed: the last 2 fiscal years, latest first.8

Period ending2025-12-312024-12-31
Research and development expenses$631.0K$776.0K
General and administrative expenses$614.0K$733.0K
Operating loss$1.2M$1.5M
Total financial expense, net$34.0K$10.0K
Net loss and comprehensive loss$1.3M$1.5M
Basic net loss per share (in Dollars per share)$0.07$0.08
Diluted net loss per share (in Dollars per share)$0.07$0.08
Weighted average number of common shares used in computing basic net loss per share (in Shares)19.6M shares18.7M shares
Weighted average number of common shares used in computing diluted net loss per share (in Shares)19.6M shares18.7M shares

Compare Raphael Pharmaceutical Inc. with another company

What it owns

What Raphael Pharmaceutical Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net$2.0K8 Dec 31, 2025$2.0K8 Dec 31, 20240%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$19.0K7 Dec 31, 2024$230.0K7 Dec 31, 2023−91.7%

Properties, in its own words

Our principal executive office is currently located at 4 Lui Paster, Tel Aviv-Jaffa, Israel 6803605.

Item 2 of the 10-K filed Mar 31, 2026.3

Leadership

Who has led Raphael Pharmaceutical Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Shlomo Pilo2022–now

President

  1. Guy Ofir2008–2010

Chief financial officer

  1. Guy Ofir2021–2023
  2. Yehuda Eliya2023
2010201520202025
Board members and other officers (13)

Former names

  • Easy Energy IncOct 24, 2007 to May 14, 20212

Timeline

  1. Sep 1, 20268-K Entered a material agreement24
  2. Jul 17, 20268-K Executive or director change25
  3. Mar 24, 20268-K Executive or director change26
  4. Aug 11, 20258-K Other events27
  5. Aug 11, 20258-K Executive or director change28
  6. Jan 14, 20258-K Executive or director change29
  7. Dec 30, 20248-K Other events30
  8. Sep 11, 20248-K Change of auditor31
  9. Jun 26, 20248-K Bylaws or fiscal year changed32
  10. May 2, 20248-K Other events33
  11. Mar 28, 20238-K Other events34
  12. Jan 26, 20238-K Executive or director change35
  13. Jan 19, 2022New chief executive Shlomo Pilo becomes CEO11

Filings

79 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 14 major events, 18 insider forms, 26 other. The latest 20:

  1. Sep 1, 20268-K CURRENT REPORT EDGAR
  2. Aug 14, 202610-Q QUARTERLY REPORT EDGAR
  3. Jul 17, 20268-K CURRENT REPORT EDGAR
  4. May 14, 202610-Q QUARTERLY REPORT EDGAR
  5. Apr 6, 20264 EDGAR
  6. Mar 31, 202610-K ANNUAL REPORT EDGAR
  7. Mar 24, 20268-K CURRENT REPORT EDGAR
  8. Nov 13, 202510-Q QUARTERLY REPORT EDGAR
  9. Sep 8, 20253 OWNERSHIP DOCUMENT EDGAR
  10. Aug 13, 202510-Q QUARTERLY REPORT EDGAR
  11. Aug 11, 20258-K CURRENT REPORT EDGAR
  12. Aug 11, 20258-K CURRENT REPORT EDGAR
  13. May 15, 202510-Q QUARTERLY REPORT EDGAR
  14. Mar 31, 202510-K ANNUAL REPORT EDGAR
  15. Mar 12, 20254 EDGAR
  16. Mar 11, 20254 EDGAR
  17. Mar 6, 20254 EDGAR
  18. Feb 13, 20253 EDGAR
  19. Jan 14, 20258-K CURRENT REPORT EDGAR
  20. Dec 30, 20248-K CURRENT REPORT EDGAR

The 79 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

SEC filer profile

How Raphael Pharmaceutical Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARRaphael Pharmaceutical Inc.1
  • CIK0001415397
  • Employer ID (EIN)26-02042843
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company3
  • Incorporated inNevada3
  • Fiscal year endsDecember 311
  • Industry code (SIC)2833 Medicinal Chemicals & Botanical Products1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business addressSuite 105 - 5348 Vegas Dr., Las Vegas, NV 891081
  • Phone702-442-11661
  • Shares outstanding20,176,418 as of Aug 14, 202610
  • Public float$9.4M as of Jun 30, 20253
  • AuditorElkana Amitai CPA, Mitzpe Netofa, Israel PCAOB ID 681600001; no auditor attestation of internal control over financial reporting3
  • On EDGAR sinceOct 24, 20071
  • Filings179 in all: 10-Q (24), 8-K (22), 4 (19), UPLOAD (15), 3 (12), CORRESP (11), EFFECT (8), 10-K (7)1
    All 36 form types

    S-1/A (7), 10-Q/A (6), POS AM (5), NT 10-Q (4), S-1 (4), 10-12G/A (3), 424B3 (3), 8-K/A (3), 10-12G (2), 4/A (2), DEF 14C (2), PRE 14C (2), SB-2/A (2), SC 13G (2), 10-K/A (1), 10KSB (1), 10KSB/A (1), 3/A (1), 5 (1), 8-A12G (1), NT 10-K (1), POS EX (1), REGDEX (1), REVOKED (1), RW (1), SB-2 (1), SC 13D (1), SC 13G/A (1)

  • Latest filingsAnnual report (10-K) Mar 31, 2026
    Quarterly report (10-Q) Aug 14, 2026
    Latest 8-K (8-K) Sep 1, 2026

Risk factors and legal proceedings

The risks Raphael Pharmaceutical Inc. names in Item 1A of its 10-K filed Mar 31, 2026: 52 risks under these headings, as written.3

  • We may not be successful in preventing the material adverse effects that any of the following risks and uncertainties may cause. These potential risks and uncertainties may not be a complete list of the risks and uncertainties facing us. There may be additional risks and uncertainties that we are presently unaware of, or presently consider immaterial, that may become material in the future and have a material adverse effect on us. You could lose all or a significant portion of your investment due to any of these risks and uncertainties.
  • Risks Related to Our Financial Condition and Capital Requirements
  • We have a limited operating history and we have incurred significant operating losses since our inception, and anticipate that we will incur continued losses for the foreseeable future.
  • We have not generated revenue from any product candidate yet and may never be profitable.
  • We do not believe that our current cash on hand will be sufficient to fund our projected operating requirements. This raises substantial doubt about our ability to continue as a going concern. In addition, the report of our independent registered public accounting firm contains an explanatory paragraph regarding substantial doubt about our ability to continue as a going concern, which could prevent us from obtaining new financing on reasonable terms or at all.
  • We expect that we will need to raise substantial additional funding before we can expect to complete the development of our RA product candidate or any other product candidate. This additional financing may not be available on acceptable terms, or at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate our product candidate development efforts or other operations.
  • The lack of an active trading market could adversely impact our ability to raise working capital and adversely impact our ability to continue operations.
  • Risks Related to Product Development, Regulatory Approval and Commercialization
  • We are heavily dependent on the success of our product candidates, which are in various stages of pre-clinical development. We cannot give any assurance that any of our product candidates will proceed to clinical development or that they will receive regulatory approval, which is necessary before they can be commercialized.
  • The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable. If we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed.
  • Clinical drug development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies may not be predictive of future study results.
  • We may find it difficult to enroll patients in our clinical studies. Difficulty in enrolling patients could delay or prevent clinical studies of our product candidates.
The other 42 risks
  • We may encounter substantial delays in our clinical studies, or we may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities.
  • Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label or result in significant negative consequences following marketing approval, if any.
  • Even if we obtain regulatory approval for a product candidate, our product candidates will remain subject to regulatory scrutiny.
  • We are subject to numerous complex regulations and failure to comply with these regulations, or the cost of compliance with these regulations, may harm our business.
  • If the market opportunities for our product candidates are smaller than we believe they are, our revenue may be adversely affected, and our business may suffer.
  • We face intense competition and rapid technological change and the possibility that our competitors may discover, develop or commercialize therapies that are similar, more advanced or more effective than ours, which may adversely affect our financial condition and our ability to successfully commercialize our product candidates.
  • The commercial success of any current or future product candidate will depend upon the degree of market acceptance by physicians, patients, third-party payors and others in the medical community.
  • The insurance coverage and reimbursement status of newly-approved products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for new or current products could limit our ability to market those products and decrease our ability to generate revenue.
  • Healthcare legislative reform measures may have a material adverse effect on our business and results of operations.
  • Risks Related to our Business and Operations
  • Reduced funding for the FDA and other government agencies and/or potentially shifting priorities under the Trump Administration could hinder the FDA’s and/or those other government agencies’ ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner, or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.
  • We currently hold no issued patents on our products, and our business employs proprietary technology (know-how) and information may be difficult to protect and/or infringe on the intellectual property rights of third parties.
  • We manage our business through our three executive officers and key consultants and are highly dependent upon our Chief Technology Officer.
  • We will need to expand our organization and we may experience difficulties in recruiting needed additional employees and consultants, which could disrupt our operations.
  • We may not be successful in our efforts to identify, license or discover additional product candidates.
  • We may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws and health information privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.
  • International expansion of our business exposes us to business, regulatory, political, operational, financial and economic risks associated with doing business outside of the U.S. or Israel.
  • If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.
  • The use of any of our product candidates could result in product liability or similar claims that could be expensive, damage our reputation and harm our business.
  • Risks Related to Our Reliance on Third Parties
  • We rely on third parties to conduct our preclinical and, in the future, clinical studies and perform other tasks for us. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or comply with regulatory requirements, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed.
  • We will rely on third parties to grow and provide us with our active pharmaceutical ingredient, or API, and formulations. Our business could be harmed if those third parties fail to provide us with sufficient quantities of our needed supplies, or fail to do so at acceptable quality levels or prices.
  • We and our collaborators and contract manufacturers are subject to significant regulation with respect to manufacturing our product candidates. The manufacturing facilities on which we rely may not continue to meet regulatory requirements and have limited capacity.
  • Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.
  • Risks Related to Ownership of Our Securities
  • Our executive officer, directors and certain stockholders who are beneficial owners of 5% or more of our outstanding Common Stock possess the majority of our voting power, and through this ownership, have the ability to control our Company and our corporate actions.
  • Investors may have difficulty in reselling their shares due to the substantial lack of liquidity of our Common Stock.
  • Our Common Stock may never be listed on a major stock exchange.
  • As a former shell company, resales of shares of our restricted Common Stock in reliance on Rule 144 of the Securities Act are subject to the requirements of Rule 144(i).
  • The securities issued in connection with the Share Exchange are restricted securities and may not be transferred in the absence of registration or the availability of a resale exemption.
  • We do not plan to declare or pay any dividends to our stockholders in the near future.
  • The requirements of being a reporting company may strain our resources and distract management.
  • If we fail to maintain proper and effective internal controls, our ability to produce accurate and timely financial statements could be impaired, which could harm our operating results, our ability to operate our business and investors’ views of us.
  • If in the future there is a trading market for our Common Stock, “penny stock” rules may make buying or selling our Common Stock difficult.
  • The sales practice requirements of the Financial Industry Regulatory Authority, or FINRA, may also limit a stockholder’s ability to buy and sell our stock.
  • Because we are a “smaller reporting company,” we will not be required to comply with certain disclosure requirements that are applicable to other public companies, and we cannot be certain if the reduced disclosure requirements applicable to smaller reporting companies will make our Common Stock less attractive to investors.
  • Risks Related to our Operations in Israel
  • Our headquarters and other significant operations are located in Israel, and, therefore, our results may be adversely affected by political, economic and military instability in Israel.
  • Conditions in Israel, including those related to recent unrest and actual or potential armed conflict in Israel and other parts of the Middle East, such as the multi-front war Israel is facing may cause interruptions or suspension of our business, which may adversely affect our business results.
  • Our operations are subject to currency and interest rate fluctuations.
  • It may be difficult to enforce a judgment of a U.S. court against us and our executive officers and directors and the Israeli experts named in this Annual Report in Israel or the U.S., to assert U.S. securities laws claims in Israel or to serve process on our executive officers and directors and these experts.
  • General Risk Factors
  • Future changes in financial accounting standards or practices may cause adverse unexpected financial reporting fluctuations and affect reported results of operations.
  • Raising additional capital would cause dilution to our existing shareholders, and may affect the rights of existing shareholders.
  • Failure in our information technology systems, including by cybersecurity attacks or other data security incidents, could significantly disrupt our operations.
  • We may be subject to securities litigation, which is expensive and could divert management attention.
  • The requirements associated with being a reporting company require significant company resources and management attention.

Legal proceedings

We are not currently a party to or subject to any material legal proceedings.

The opening of Item 3, Legal Proceedings.3

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
    SEC EDGAROther events
  28. 28
  29. 29
  30. 30
    SEC EDGAROther events
  31. 31
  32. 32
  33. 33
    SEC EDGAROther events
  34. 34
    SEC EDGAROther events
  35. 35